Structural and functional impairment patterns of the heart in a group of HIV-infected adults
AbstractCardiovascular disease is an increasingly important issue in human immunodeficiency viral (HIV)-infected individuals. Despite treatment with potent and effective combination antiretroviral medications, the incidence of heart diseases in the population living with HIV remains significantly higher than that in non-infected individuals. An intimate knowledge of opportunistic infections affecting the heart, effects of high antiretroviral therapy (HART) and therapy for opportunistic infections on the heart is needed to be able to formulate a differential diagnosis. Cardiovascular risk reduction and lifestyle modifications are essential and careful selection of the antiretroviral drugs according to underlying cardiovascular risk factors of great importance. A better understanding of how different pathogenetic issues can coexist will allow the development of methods aimed at enhancing the immune response to control HIV-mediated infections, as well as the production of therapeutic agents for the access to antiretroviral treatment with little or no impact on lipid and glucose metabolism of importance to reduce cardiovascular disease in HIV.
Keywords:HIV-infection; AIDS; cardiovascular disease; cardiomyopathy; ischemic heart disease; arrhythmia; antiretroviral therapy
Funding. The study had no sponsor support.
Conflict of interest. The authors declare no conflict of interest.
For citation: Chanakchian F.N., Gulyaev N.I., Ivanov D.S., Novikova E.A. Structural and functional impairment patterns of the heart in a group of HIV-infected adults. Kardiologiya: novosti, mneniya, obuchenie [Cardiology: News, Opinions, Training]. 2024; 12 (1): 36–43. DOI: https://doi.org/10.33029/2309-1908-2024-12-1-36-43 (in Russian)
References
1. Pirogova I.A. The prevalence of HIV-infection in Russia. Bulletin SMUS 74. 2017; 4 (19): 45–9. (In Russian)
2. Ruiz G.O., Herrera C.F.L., Bohórquez J.A.M., et al. Mortality in patients with acquired human immunodeficiency virus infection hospitalized in an intensive care unit during the period 2017–2019. Sci Rep. 2022; 12 (15644). DOI: https://doi.org/10.1038/s41598-022-19904
3. Ewings F.M., Bhaskaran K., McLean K., et al. UK Register of HIV Seroconverters. Survival following HIV infection of a cohort followed up from seroconversion in the UK. AIDS. 2008; 22 (1). P. 89–95. DOI: https://doi.org/10.1097/QAD.0b013e3282f3915e
4. Teeraananchai S., Kerr S.J., Amin J., et al. Life expectancy of HIV-positive people after starting combination antiretroviral therapy: a meta-analysis. HIV Med. 2017; 18 (4): 256–66. DOI: https://doi.org/10.1111/hiv.12421
5. Brouch D., Tashtish N., Di Felice C., et al. Human Immunodeficiency Virus Infection and Risk of Heart Failure Rehospitalizations. Am J Cardiol. 2019; 124 (8): 1232–8. DOI: https://doi.org/10.1016/j.amjcard.2019.07.034
6. Alonso A., Barnes A.E., Guest J.L., et al. HIV Infection and Incidence of Cardiovascular Diseases: An Analysis of a Large Healthcare Database. J Am Heart Assoc. 2019; 8 (14): e012241. DOI: https://doi.org/10.1161/JAHA.119.012241
7. Manga P., McCutcheon K., Tsabedze N., et al. HIV and Nonischemic Heart Disease. JACC. 2017; 69 (1): 83–91. DOI: https://doi.org/doi.org/10.1016/j.jacc.2016.09.977
8. Erqou S., Lodebo B.T., Masri A., et al. Cardiac Dysfunction Among People Living With HIV: A Systematic Review and Meta-Analysis. JACC: Heart Failure. 2019; 7 (2): 98–108. DOI: https://doi.org/doi.org/10.1016/j.jchf.2018.10.006
9. Belkin M.N., Uriel N. Heart health in the age of highly active antiretroviral therapy: a review of HIV cardiomyopathy. Curr Opin Cardiol. 2018; 33 (3): 317–24. DOI: https://doi.org/10.1097/HCO.0000000000000513
10. Freiberg M.S., Chang C.C., Kuller L.H., et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013; 173 (8): 614–22. DOI: https://doi.org/10.1001/jamainternmed.2013.3728
11. Lang S., Boccara F., Mary-Krause M., Cohen A. Epidemiology of coronary heart disease in HIV-infected versus uninfected individuals in developed countries. Arch Cardiovasc Dis. 2015; 108 (3): 206–15. DOI: https://doi.org/doi.org/10.1016/j.acvd.2015.01.004
12. Paisible A.L., Chang C.C., So-Armah K.A., et al. HIV infection, cardiovascular disease risk factor profile, and risk for acute myocardial infarction. J Acquir Immune Defic Syndr. 2015; 68 (2): 209–16. DOI: https://doi.org/10.1097/QAI.0000000000000419
13. Shah A.S.V., Stelzle D., Lee K.K., et al. Global Burden of Atherosclerotic Cardiovascular Disease in People Living With HIV: Systematic Review and Meta-Analysis. Circulation. 2018; 138 (11): 1100–12. DOI: https://doi.org/10.1161/CIRCULATIONAHA.117.033369
14. Goldblum N., Daefler S., Llana T., et al. Susceptibility to HIV-1 infection of a human B-lymphoblastoid cell line, DG75, transfected with subgenomic DNA fragments of Epstein-Barr virus. Dev Biol Stand. 1990; 72: 309–13. PMID: 2178126.
15. Teer E., Dominick L., Mukonowenzou N.C., Essop M.F. HIV-Related Myocardial Fibrosis: Inflammatory Hypothesis and Crucial Role of Immune Cells Dysregulation. Cells. 2022; 11 (18): 2825. DOI: https://doi.org/10.3390/cells11182825
16. de la Asunción J.G., Del Olmo M.L., Gómez-Cambronero L.G., et al. AZT induces oxidative damage to cardiac mitochondria: protective effect of vitamins C and E. Life Sci. 2004; 76 (1): 47–56. DOI: https://doi.org/10.1016/j.lfs.2004.06.020
17. Siddiqui J., Samuel S.K., Hayward B., et al. HIV-associated wasting prevalence in the era of modern antiretroviral therapy. AIDS. 2022; 36 (1): 127–135. DOI: https://doi.org/10.1097/QAD.0000000000003096
18. Strategies for Management of Antiretroviral Therapy (SMART) Study Group; El-Sadr W.M., Lundgren J., Neaton J.D., et al. CD 4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006; 355 (22): 2283–96. DOI: https://doi.org/10.1056/NEJMoa062360
19. Fishbein G.A., Micheletti R.G., Currier J.S., et al. Atherosclerotic oxalosis in coronary arteries. Cardiovascular Pathology. 2008; 17 (2): 117–23. DOI: https//doi.org/10.1016/j.carpath.2007.07.002
20. Thienemann F., Sliwa K., Rockstroh J.K. HIV and the heart: the impact of antiretroviral therapy: a global perspective. Eur H J. 2013; 46 (7): 3538–46. DOI: https://doi.org/10.1093/eurheartj/eht388
21. So-Armah K., Benjamin L.A., Bloomfield G.S., et al. HIV and cardiovascular disease. The Lancet HIV. 2020; 7 (4): 279–93. DOI: https://doi.org/10.1016/s2352-3018(20)30036-9
22. Vachiat A., McCutcheon K., Tsabedze N., et al. HIV and Ischemic Heart Disease. JACC. 2017; 69 (1): 73–82. https://doi.org/10.1016/j.jacc.2016.09.979
23. Tseng Z.H., Secemsky E.A., Dowdy D., et al. Sudden cardiac death in patients with human immunodeficiency virus infection. J Am Coll Cardiol. 2012; 59 (21): 1891–6. DOI: https://doi.org/10.1016/j.jacc.2012.02.024
24. Abudan A.A., Vaidya V.R., Tripathi B., et al. Burden of arrhythmia in hospitalized HIV patients. Clin Cardiol. 2021; 44 (44): 66–77. DOI: https://doi.org/10.1002/clc.23506
25. Huikuri H.V., Castellanos A., Myerburg R.J. Sudden death due to cardiac arrhythmias. N Engl J Med. 2001; 345: 1473–82. DOI: https://doi.org/10.1056/NEJMra000650
26. Gebo K.A., Burkey M.D., Lucas G.M., et al. Incidence of, risk factors for, clinical presentation, and 1-year outcomes of infective endocarditis in an urban HIV cohort. J Acquir Immune Defic Syndr. 2006; 43 (4): 426–32. DOI: https://doi.org/10.1097/01.qai.0000243120.67529.78
27. Feinstein M.J., Hsue P.Y., Benjamin L.A., et al. Characteristics, prevention, and management of cardiovascular disease in people living with HIV: a scientific statement from the American Heart Association. Circulation. 2019; 140: 98–e124. DOI: https://doi.org/10.1161/CIR.0000000000000695
28. Bai Y.L., Liu H.B., Sun B., et al. HIV Tat protein inhibits hERG K+ channels: a potential mechanism of HIV infection induced LQTs. J Mol Cell Cardiol. 2011; 51: 876–80. DOI: https://doi.org/10.1016/j.yjmcc.2011.07.017
29. Brouillette J., Cyr S., Fiset C. Mechanisms of arrhythmia and sudden cardiac death in patients with HIV infection. Can J Cardiol. 2019; 35: 310–9. DOI: https://doi.org/10.1016/j.cjca.2018.12.015
30. Nou E., Lo J., Grinspoon S.K. Inflammation, immune activation, and cardiovascular disease in HIV. AIDS. 2016; 30: 1495–509. DOI: https://doi.org/10.1097/QAD.0000000000001109
31. Es-Salah-Lamoureux Z., Jouni M., Malak O.A., et al. HIV-Tat induces a decrease in IKr and IKsvia reduction in phosphatidylinositol-(4,5)-bisphosphate availability. J Mol Cell Cardiol. 2016; 99: 1–13. DOI: https://doi.org/10.1016/j.yjmcc.2016.08.022
32. Pastori D., Mezzaroma I., Pignatelli P., et al. Atrial fibrillation and human immunodeficiency virus type-1 infection: a systematic review. Implications for anticoagulant and antiarrhythmic therapy. Br J Clin Pharmacol. 2019; 85 (3): 508–15. DOI: https://doi.org/10.1111/bcp.13837
33. Hsu J.C., Li Y., Marcus G.M., et al. Atrial fibrillation and atrial flutter in human immunodeficiency virus-infected persons: incidence, risk factors, and association with markers of HIV disease severity. J Am Coll Cardiol. 2013; 61 (22): 2288–95. DOI: https://doi.org/10.1016/j.jacc.2013.03.022
34. Esterly J.S., Darin K.M., Gerzenshtein L., et al. Clinical implications of antiretroviral drug interactions with warfarin: a case-control study. J Antimicrob Chemother. 2013; 68 (6): 1360–3. DOI: https://doi.org/10.1093/jac/dkt043
35. Egan G., Hughes C.A., Ackman M.L. Drug interactions between antiplatelet or novel oral anticoagulant medications and antiretroviral medications. Ann Pharmacother. 2014; 48 (6): 734–40. DOI: https://doi.org/10.1177/1060028014523115
36. Bates D., Dalton B., Gilmour J., Kapler J. Venous thromboembolism due to suspected interaction between rivaroxaban and nevirapine. Can J Hosp Pharm. 2013; 66 (2): 125–9. DOI: https://doi.org/10.4212/cjhp.v66i2.1235